搜索范围
U0800000
应用筛选条件
关键词:'U0800000'
显示 1-30 #N/A 89 条结果 关于 "U0800000" 范围 论文
G Ia Khismatullina et al.
Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, (4)(4), 60-65 (2013-02-14)
The therapeutic efficiency of ursosan in 64 overweight patients with chronic noncalculous cholecystitis and dysfunction of biliary tract was evaluated. Including of ursosan in the complex therapy of patients with chronic noncalculous cholecystitis enhances the efficiency of therapy, causes the
L Serfaty et al.
Gastroenterologie clinique et biologique, 34(10), 516-522 (2010-07-09)
Colorectal cancer is respectively the third and second most common cancer among men and women in France. Interest in chemoprevention for colorectal cancer has increased over the last two decades. Beside non-steroidal anti-inflammatory drugs, ursodeoxycholic acid (UDCA) may have chemopreventive
Patricia Martínez-Moya et al.
International immunopharmacology, 15(2), 372-380 (2012-12-19)
The denomination of inflammatory bowel disease comprises a group of chronic inflammatory diseases of the digestive tract, ulcerative colitis and Crohn's disease being the most important conditions. Bile acids may play a role both in etiology and pharmacology of this
[The use of hepatic protectors in clinical practice].
O N Minushkin et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 112(10 Pt 2), 67-72 (2012-12-20)
Sara M Centuori et al.
Digestive diseases and sciences, 59(10), 2367-2380 (2014-07-17)
A high-fat diet coincides with increased levels of bile acids. This increase in bile acids, particularly deoxycholic acid (DCA), has been strongly associated with the development of colon cancer. Conversely, ursodeoxycholic acid (UDCA) may have chemopreventive properties. Although structurally similar
Ludovico Abenavoli et al.
Annals of hepatology, 12(1), 152-155 (2013-01-08)
Cyproterone acetate (CPA) is an oral anti-androgen commonly used to treat advanced prostate cancer. A variety of hepatotoxic reactions has been reported with CPA. Here we describe a case of a male patient who developed severe drug-induced hepatotoxicity during the
Sheng-di Wu et al.
European journal of gastroenterology & hepatology, 24(11), 1247-1253 (2012-08-07)
The aim of this study was to evaluate the effects of ursodeoxycholic acid on patients with nonalcoholic steatohepatitis using meta-analysis. PubMed, EMBASE, Web of Science, Cochrane Library, Chinese Biomedical Databases, and article references were searched. We included randomized controlled trials
Li-Na Zhang et al.
Hepatology (Baltimore, Md.), 58(1), 264-272 (2013-02-15)
The biochemical response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis is a strong predictor of long-term outcome and thus facilitates the rapid identification of patients needing new therapeutic approaches. Numerous criteria for predicting outcome of treatment have been studied
Qing Tang et al.
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 15(9), 756-758 (2013-09-17)
To analyze the effects of ursodeoxycholic acid (UDCA) on the mRNA expression of multidrug resistance protein 3 (MDR3) and farnesoid X receptor (FXR) in infants with cholestatic hepatitis. Twenty-eight infants who were diagnosed with cholestatic hepatitis between July 2008 and
Walee Chamulitrat et al.
Molecular pharmacology, 84(5), 696-709 (2013-08-27)
Ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE) is a hepatoprotectant in inhibiting apoptosis, inflammation, and hyperlipidemia in mouse models of nonalcoholic steatohepatitis (NASH). We studied the ability of UDCA-LPE to inhibit palmitate (Pal)-induced apoptosis in primary hepatocytes and delineate cytoprotective mechanisms. We showed that
Jelena S Rudic et al.
The Cochrane database of systematic reviews, 12, CD000551-CD000551 (2012-12-14)
Ursodeoxycholic acid is administered to patients with primary biliary cirrhosis, a chronic progressive inflammatory autoimmune-mediated liver disease with unknown aetiology. Despite its controversial effects, the U.S. Food and Drug Administration has approved its usage for primary biliary cirrhosis. To assess
Heather Mortiboys et al.
Brain : a journal of neurology, 136(Pt 10), 3038-3050 (2013-09-04)
Previous drug screens aiming to identify disease-modifying compounds for Parkinson's disease have typically been based on toxin-induced in vitro and in vivo models of this neurodegenerative condition. All these compounds have failed to have a reliable disease-modifying effect in subsequent
Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis.
Yannick Bacq et al.
Gastroenterology, 143(6), 1492-1501 (2012-08-16)
We performed a meta-analysis to evaluate the effects of ursodeoxycholic acid (UDCA) on pruritus, liver test results, and outcomes of babies born to women with intrahepatic cholestasis of pregnancy (ICP). We performed a systematic review of 9 published, randomized controlled
V V Kollerov et al.
Steroids, 78(3), 370-378 (2013-01-22)
Selected actinobacteria and filamentous fungi of different taxonomy were screened for the ability to carry out regio- and stereospecific hydroxylation of lithocholic acid (LCA) at position 7β. The production of ursodeoxycholic acid (UDCA) was for the first time shown for
[Using ursodez in the treatment of refractory form of gastroesophageal reflux disease].
A M Osadchuk et al.
Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, (4)(4), 74-75 (2013-02-14)
Davide Festi et al.
Current clinical pharmacology, 2(2), 155-177 (2008-08-12)
Ursodeoxycholic acid (UDCA), previously used for cholesterol gallstone dissolution, is currently considered the first choice therapy for many forms of cholestatic syndromes. Many mechanisms and sites of action have been proposed for UDCA, but definitive data are still missing regarding
Mark Mapstone et al.
Nature medicine, 20(4), 415-418 (2014-03-13)
Alzheimer's disease causes a progressive dementia that currently affects over 35 million individuals worldwide and is expected to affect 115 million by 2050 (ref. 1). There are no cures or disease-modifying therapies, and this may be due to our inability
John E Eaton et al.
Gastroenterology, 145(3), 521-536 (2013-07-06)
Primary sclerosing cholangitis (PSC), first described in the mid-1850s, is a complex liver disease that is heterogeneous in its presentation. PSC is characterized by chronic cholestasis associated with chronic inflammation of the biliary epithelium, resulting in multifocal bile duct strictures
Nianbai Fang et al.
Experimental biology and medicine (Maywood, N.J.), 240(4), 488-497 (2014-10-12)
High-performance liquid chromatography (HPLC) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) are generally accepted as the preferred techniques for detecting and quantitating analytes of interest in biological matrices on the basis of the rule that one chemical compound yields one LC-peak
Sui Peng et al.
American journal of physiology. Gastrointestinal and liver physiology, 307(2), G129-G139 (2014-05-24)
Hydrophobic bile acids like deoxycholic acid (DCA), which cause oxidative DNA damage and activate NF-κB in Barrett's metaplasia, might contribute to carcinogenesis in Barrett's esophagus. We have explored mechanisms whereby ursodeoxycholic acid (UDCA, a hydrophilic bile acid) protects against DCA-induced
Michele Pier Luca Guarino et al.
World journal of gastroenterology, 19(31), 5029-5034 (2013-08-22)
Gallstone disease represents an important issue in the healthcare system. The principal non-invasive non-surgical medical treatment for cholesterol gallstones is still represented by oral litholysis with bile acids. The first successful and documented dissolution of cholesterol gallstones was achieved in
Kidist K Yimam et al.
Autoimmunity reviews, 13(4-5), 445-450 (2014-01-16)
Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease of the liver and that is characterized by progressive inflammation, fibrosis, and stricturing of the intrahepatic and extrahepatic bile ducts. It is progressive in most patients and leads to cirrhosis. It
Jong-Min Han et al.
Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, 65(6), 837-844 (2013-01-10)
Artemisia capillaris has been widely used as a traditional herbal medicine in the treatment of liver diseases. However, no previous study has investigated whether A. capillaries alone is effective in treating pathological conditions associated with cholestatic liver injury. In the
Ursodiol: good drug makes good.
Teresa A Brentnall
Gastroenterology, 124(4), 1139-1140 (2003-04-03)
Susana Solá et al.
Current issues in molecular biology, 9(2), 123-138 (2007-05-11)
Apoptosis represents a universal and exquisitely efficient cellular suicide pathway essential for a variety of normal biological processes ranging from embryonic development to ageing. In fact, tissue homeostasis is dependent on the perfect balance between positive and negative signals that
Valerie A San Luis et al.
The Annals of pharmacotherapy, 41(11), 1867-1872 (2007-10-04)
To review the role of ursodeoxycholic acid (ursodiol) in treating parenteral nutrition-associated cholestasis (PNAC). A MEDLINE (1950-May 2007) search was performed using the key terms parenteral nutrition, cholestasis, ursodeoxycholic acid, and ursodiol. All English-language articles that evaluated the safety and
Peter P Rainer et al.
Heart (British Cardiac Society), 99(22), 1685-1692 (2013-07-31)
High bile acid serum concentrations have been implicated in cardiac disease, particularly in arrhythmias. Most data originate from in vitro studies and animal models. We tested the hypotheses that (1) high bile acid concentrations are arrhythmogenic in adult human myocardium
P Manousou et al.
Clinical and experimental immunology, 172(1), 9-15 (2013-03-14)
The CXC chemokines, monokine induced by interferon (IFN)-gamma (MIG) (CXCL9), IFN-gamma-induced protein 10 (IP-10) (CXCL10) and IFN-inducible T cell alpha chemoattractant (I-TAC) (CXCL11), are known to attract CXCR3- (CXCR3A and CXCR3B) T lymphocytes. We investigated MIG, IP-10 and I-TAC mRNAs
Nathalie Martin et al.
Molecular cancer, 13, 151-151 (2014-06-16)
Epidemiological data show that the incidence of carcinomas in humans is highly dependent on age. However, the initial steps of the age-related molecular oncogenic processes by which the switch towards the neoplastic state occurs remain poorly understood, mostly due to
Kenichi Harada et al.
Digestive diseases and sciences, 58(10), 3037-3043 (2013-06-15)
Primary biliary cirrhosis (PBC), characterized by cholangitis and loss of intrahepatic small bile ducts, predominantly affects middle-aged females. We have reported that fractalkine expression associated with chronic inflammation is observed in the damaged bile ducts and periductal vessels of PBC
1/3